What is the 13F Pro Quality Score for AVBP?

13F Pro ranks ArriVent BioPharma, Inc. (AVBP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVBP's current score at https://13fpro.ai/research/AVBP (free sign-up required for the full ranking).

Where does 13F Pro source AVBP data?

All ArriVent BioPharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. ArriVent BioPharma, Inc. files with the SEC under CIK 1868279. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVBP in?

ArriVent BioPharma, Inc. (AVBP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AVBP research updated on 13F Pro?

AVBP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ArriVent BioPharma, Inc.(AVBP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1868279 AVBP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AVBP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ArriVent BioPharma, Inc. (AVBP), a Healthcare sector company. AVBP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), ArriVent BioPharma, Inc. reports net income of $-43.3M, free cash flow of $-41.9M. Top institutional holders of AVBP by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, INFINITUM ASSET MANAGEMENT,, Hillhouse Capital Advisors, Ltd., based on the most recent SEC filings. AVBP trades on the Nasdaq exchange and files with the SEC under CIK 1868279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ArriVent BioPharma, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-43.3M

Free Cash Flow

Q1 2026

$-41.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-106.6% YoY

$-166.3MFY 2025

FY22 —FY23 $-69.3MFY24 $-80.5MFY25 $-166.3M

Operating Income

-88.2% YoY

$-177.5MFY 2025

FY22 —FY23 $-74.6MFY24 $-94.3MFY25 $-177.5M

EPS (Diluted)

-68.8% YoY

$-4.32FY 2025

FY22 —FY23 $-2.13FY24 $-2.56FY25 $-4.32

Total Assets

+21.2% YoY

$333.2MFY 2025

FY22 —FY23 $163.1MFY24 $274.9MFY25 $333.2M

Op. Cash Flow

-128.7% YoY

$-160.6MFY 2025

FY22 —FY23 $-55.8MFY24 $-70.2MFY25 $-160.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	$-166.3M -106.6%	$-80.5M -16.1%	$-69.3M	—
Operating Income	$-177.5M -88.2%	$-94.3M -26.4%	$-74.6M	—
EPS (Diluted)	$-4.32 -68.8%	$-2.56 -20.2%	$-2.13	—
Total Assets	$333.2M +21.2%	$274.9M +68.6%	$163.1M	—
Operating Cash Flow	$-160.6M -128.7%	$-70.2M -25.7%	$-55.8M	—

AI Insight: AVBP Financial Trends

ArriVent remains a pre-revenue clinical-stage company burning ~$42M in operating cash in Q1 2026, with equity rising to $324M suggesting recent capital raises.

• Equity rose from $203M in Q1 2025 to $324M in Q1 2026, indicating meaningful capital raises over the past year.

• Operating losses have re-accelerated: op income worsened from -$39M in Q4 2025 to -$46M in Q1 2026.

• Q1 2025 was an outlier quarter with net loss of -$64M and op CF of -$68M; subsequent quarters show partial normalization.

⚠ Operating cash burn of -$42M in Q1 2026 is rising; runway depends entirely on continued equity capital raises with zero revenue.

⚠ Equity jumped from $250M in Q2 2025 to $307M in Q4 2025 and $324M in Q1 2026 — monitor dilution pace.

⚠ No debt reported across all eight quarters; watch for any shift to debt financing as burn rate increases.

AI Insight: AVBP Ratio Trends

Return metrics are deteriorating sharply into Q1 2026, with ROIC falling to -56.9% — the worst level since the Q1 2025 spike.

• ROIC worsened from -34.6% in Q2 2024 to -56.9% in Q1 2026, a 22pp deterioration over seven quarters.

• ROE plunged to -127.2% in Q1 2025 before partially recovering to -53.5% in Q1 2026, suggesting a large one-off loss event.

• ROA tracked from -28.3% in Q2 2024 to -49.6% in Q1 2026, reflecting deepening asset-level losses with no revenue offset visible.

⚠ Operating margin and D/E data are entirely absent — impossible to assess cost structure or leverage trajectory from available figures.

⚠ ROIC reaccelerated to -56.9% in Q1 2026 after brief stabilization in Q3–Q4 2025; any further deterioration would approach Q1 2025 lows.

Get alerted when AVBP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ArriVent BioPharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVBP

SUVRETTA CAPITAL MANAGEMENT, LLC
$101.5M4,401,083 sh
INFINITUM ASSET MANAGEMENT, LLC
$95.7M4,148,923 sh
Hillhouse Capital Advisors, Ltd.
$90.6M3,929,117 sh
ORBIMED ADVISORS LLC
$69.8M3,027,328 sh
FMR LLC
$69.6M3,016,132 sh
BlackRock, Inc.
$58.4M2,530,301 sh
Octagon Capital Advisors LP
$45.5M1,971,054 sh
Novo Holdings A/S
$44.8M1,942,142 sh
Sofinnova Ventures Inc
$39.1M1,696,752 sh
VANGUARD CAPITAL MANAGEMENT LLC
$35.3M1,528,893 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$101.5M	4,401,083
INFINITUM ASSET MANAGEMENT, LLC	$95.7M	4,148,923
Hillhouse Capital Advisors, Ltd.	$90.6M	3,929,117
ORBIMED ADVISORS LLC	$69.8M	3,027,328
FMR LLC	$69.6M	3,016,132
BlackRock, Inc.	$58.4M	2,530,301
Octagon Capital Advisors LP	$45.5M	1,971,054
Novo Holdings A/S	$44.8M	1,942,142
Sofinnova Ventures Inc	$39.1M	1,696,752
VANGUARD CAPITAL MANAGEMENT LLC	$35.3M	1,528,893

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVBP on your watchlist

Track score changes the day ArriVent BioPharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVBP a good stock to buy?

13F Pro's AI-powered analysis of ArriVent BioPharma, Inc. (AVBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVBP are available on the AVBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AVBP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ArriVent BioPharma, Inc.'s investment landscape.